Tinea Corporis: Ringworm of the Body

Clinical Overview

Tinea corporis, commonly called ringworm, is a superficial fungal infection of the body caused by dermatophytes (keratinolytic fungi), most commonly Trichophyton rubrum, Microsporum canis, and Trichophyton mentagrophytes. The infection manifests as scaling plaques with characteristic annular (ring-shaped) appearance, hence the common name "ringworm" (though the condition is not caused by worms). Tinea corporis typically presents as well-demarcated patches or plaques with erythematous borders and often central clearing, though morphology varies considerably. The condition is contagious, spreading through direct contact with infected individuals or animals, contact with contaminated fomites (objects), or autoinoculation from other infected body areas. Tinea corporis affects individuals across all age groups and is more common in warm, humid climates and during summer months. Rapid diagnosis through KOH preparation or fungal culture combined with appropriate topical or systemic antifungal therapy results in cure rates >90%.

Epidemiology

Tinea corporis affects approximately 8-10% of the general population and represents one of the most common superficial fungal infections worldwide. Incidence is higher in warm, humid climates (subtropical and tropical regions show 15-20% prevalence compared to 5-8% in temperate climates). Seasonal variation is evident, with incidence peaks in summer and early autumn in temperate climates. The condition shows no significant gender predominance. Age distribution shows bimodal pattern: first peak in young children (particularly 3-14 years old) and second peak in older adults. Risk factors include: contact with infected individuals (family members, sexual partners), contact with infected animals (particularly cats with microsporum canis infection), occupational exposures (manual laborers, farmers), poor hygiene, immunocompromised status (HIV infection, systemic corticosteroid use, malignancy), diabetes mellitus, and atopic dermatitis or other underlying skin conditions predisposing to infection. Autoinoculation from other infected body sites (tinea pedis, tinea unguium) is common; approximately 30-40% of patients with tinea corporis have concurrent tinea pedis.

Pathophysiology

Tinea corporis develops through dermatophyte invasion of the stratum corneum, followed by local immune response and inflammatory reaction. Dermatophytes are keratinophilic fungi possessing keratinolytic enzymes allowing them to invade keratin-rich structures (skin, hair, nails). When dermatophyte spores or hyphae contact intact or slightly damaged epidermis, they germinate and invade the stratum corneum, typically without penetrating viable epidermis. The fungus produces proteolytic and keratinolytic enzymes (including subtilisin-like serine proteases) that degrade keratin and facilitate invasion. Local immune response to fungal antigens includes both innate and adaptive immunity: innate immunity involves antimicrobial peptides, complement activation, and neutrophil infiltration; adaptive immunity includes Th1-mediated response with IFN-γ production and development of dermatophyte-specific T cell responses. The inflammatory response results in erythema, scaling, and characteristic border formation with central clearing as the host immune response contains and clears infection from central lesion area while infection advances peripherally. The characteristic ring shape results from this dynamic edge of advancing infection. In immunocompetent individuals, local immune response typically controls infection, with Th1-mediated cellular immunity being essential for clearance; immunocompromised individuals show reduced ability to clear infection and develop more extensive or atypical disease.

Clinical Presentation

Tinea corporis typically presents as scaling plaques with well-demarcated erythematous borders and often lighter, less inflamed central area (annular appearance). Lesions are typically 1-10 cm in diameter but may exceed this size, and coalescence can create larger plaques. The scaling is typically fine, superficial, and easily removed. Pruritus is variable (present in 50-70% of patients) and may be intense or minimal. Common sites include arms, legs, trunk, and face; any body area except palms and soles (which are not typically affected due to thicker stratum corneum and different skin flora) may be involved. Lesions may occur as solitary plaques or may be multiple. Secondary bacterial infection occurs in 10-20% of cases, manifesting as increased erythema, purulence, regional lymphadenopathy, and potential cellulitis. The course without treatment is variable: some lesions resolve spontaneously within weeks (estimated 10-15% of cases), while untreated infection may persist for months to years. Most lesions gradually improve with time but not without treatment; this may be due to natural host immune response or decreased environmental favorability for fungal growth.

Diagnosis

Diagnosis of tinea corporis requires clinical suspicion based on annular scaling plaques combined with confirmatory testing. Key diagnostic features include: (1) well-demarcated scaling plaques with erythematous borders; (2) central clearing creating ring shape (though not all cases show this pattern); (3) location on body surface (excluding palms/soles); (4) contagion history (contact with infected individuals or animals). Potassium hydroxide (KOH) preparation is rapid, inexpensive confirmatory test: scales obtained with scalpel from active lesion border are treated with 10% KOH solution, which dissolves cellular material and leaves fungal elements (hyphae, spores) visible under microscopy (40-60% sensitivity). Fungal culture on Sabouraud dextrose agar or dermatophyte test medium (DTM) provides definitive organism identification and is recommended for treatment-resistant cases or epidemiologically important identifications (e.g., zoophilic organisms); culture sensitivity approaches 90% when appropriate specimens collected. Dermoscopy reveals characteristic features including "red globules" (dilated capillaries at lesion borders visible as red dots) and "peripheral scales." Wood lamp (325-365 nm ultraviolet light) typically shows no fluorescence (most tinea corporis infections are non-fluorescent; only occasional Microsporum infections show faint blue-green fluorescence). Differential diagnosis includes: pityriasis rosea (distinguished by collarette scale on individual lesions, central clearing that is typically more symmetric, and self-limited course), psoriasis (typically less pruritic, different morphology, family history), seborrheic dermatitis, and other scaling conditions. For treatment-resistant disease, biopsy may be considered to assess for alternative diagnoses.

Treatment Algorithm

Treatment of tinea corporis depends on extent of disease. Localized infections (limited number of lesions, <5% body surface area) are treated with topical antifungals; extensive infections (numerous lesions or >5-10% body surface area) typically require systemic therapy for reliable cure.

Topical antifungals are first-line for localized tinea corporis. Effective agents include: azole antifungals (ketoconazole 2% cream, miconazole 2% cream, clotrimazole 1% cream) applied twice daily for 2-4 weeks; allylamines (terbinafine 1% cream) applied once to twice daily for 2 weeks; and others including tolnaftate 1% or undecylenic acid. Most topical antifungals show equivalent efficacy; choice depends on patient preference, cost, and availability. Azoles work by inhibiting fungal sterol synthesis; allylamines inhibit ergosterol synthesis. Application instructions should emphasize extending treatment 1 inch beyond lesion borders to address subclinical infection. Duration of therapy should continue for 1-2 weeks after clinical apparent clearance to reduce relapse risk.

Systemic antifungals are indicated for: (1) extensive tinea corporis involving >10% body surface area; (2) lesions involving face, hair-bearing areas, or genitals; (3) immunocompromised patients; (4) treatment failure with topical therapy; (5) inability to apply topical therapy due to extent of disease. First-line systemic agents include: terbinafine 250 mg once daily for 2-4 weeks (typical course 2-4 weeks depending on extent and organism; terbinafine is fungicidal against dermatophytes and typically requires shorter treatment duration), or itraconazole 200-400 mg once daily for 2-4 weeks (slower acting than terbinafine but equally effective; may require longer duration than terbinafine). Griseofulvin 500 mg twice daily for 2-4 weeks is an alternative though less preferred than modern agents due to slower action and need for higher doses. Monitoring of liver function (baseline and periodic transaminases) is recommended for prolonged systemic therapy, particularly in patients with underlying hepatic disease.

Supportive measures including keeping infected areas clean and dry, reducing friction, and avoiding skin-to-skin contact with others minimize disease spread and improve healing. Patients should be counseled regarding contagion: direct contact transmission to others and autoinoculation to new body areas can occur; hand hygiene after contact with lesions is essential.

Secondary bacterial infections require appropriate antibiotic therapy. Culture-guided therapy is preferred; empiric treatment with oral cephalexin 500 mg four times daily or clindamycin 300-450 mg three times daily for 10-14 days is appropriate for non-severe cellulitis-associated infection.

Prognosis

The prognosis of tinea corporis with appropriate antifungal therapy is excellent: cure rates exceed 90% with appropriate topical or systemic therapy. Factors influencing outcomes include: compliance with antifungal therapy (extending treatment for 1-2 weeks after apparent clearance reduces relapse), elimination of sources of reinfection (treating concurrent tinea pedis or other infected sites, limiting contact with infected individuals or animals), and host factors (immunocompromised patients may require longer or repeated courses of therapy). Relapse rates of 10-15% occur if therapy is discontinued prematurely or if sources of reinfection are not eliminated. In immunocompromised individuals (HIV with CD4 <200, severe immunosuppression), disease may be more extensive and difficult to treat; however, immune reconstitution typically results in disease resolution.

When to See a Dermatologist

Evaluation by a healthcare provider is appropriate if tinea corporis is suspected to confirm diagnosis and initiate appropriate therapy. Dermatology referral is recommended if: (1) diagnosis is uncertain; (2) extensive disease is present; (3) disease fails to respond to appropriate topical or systemic therapy after 4-6 weeks; (4) patient is immunocompromised; (5) secondary bacterial infection develops.

Frequently Asked Questions

Q: Is tinea corporis contagious? A: Yes, tinea corporis is contagious. Transmission occurs through direct contact with infected individuals, contact with animals (particularly cats), or contact with contaminated objects. Autoinoculation to new body areas can occur through scratching.

Q: Can I get tinea corporis from my pet? A: Yes, some dermatophytes infect animals, particularly cats and dogs. Microsporum canis commonly infects cats and can be transmitted to humans. If pet tinea is suspected, veterinary evaluation and treatment may be necessary.

Q: How long does tinea corporis treatment take? A: Topical antifungals typically require 2-4 weeks of treatment; systemic antifungals require 2-4 weeks depending on extent and organism. Treatment should continue for 1-2 weeks after lesions appear to clear to reduce relapse risk.

Q: Can tinea corporis spread to other body parts? A: Yes, autoinoculation through scratching and contact can spread tinea corporis to other areas. Persons with active infection should practice good hand hygiene and avoid contact with other body areas.

References